無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の免疫腫瘍治療市場 (モノクローナル抗体、免疫チェックポイント阻害剤、免疫系変調因子、癌ワクチン):世界の業界見通し、包括的分析、予測

Immuno-oncology Therapy Market (Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines): Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022

発行 Zion Market Research 商品コード 630429
出版日 ページ情報 英文 110 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
世界の免疫腫瘍治療市場 (モノクローナル抗体、免疫チェックポイント阻害剤、免疫系変調因子、癌ワクチン):世界の業界見通し、包括的分析、予測 Immuno-oncology Therapy Market (Monoclonal Antibodies, Immune Checkpoint Inhibitors (PD-1/PD-L1 and CTLA-4), Immune System Modulators, and Cancer Vaccines): Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 - 2022
出版日: 2018年01月17日 ページ情報: 英文 110 Pages
概要

当レポートでは、世界の免疫腫瘍治療市場について調査し、市場の概要と治療タイプ別、治療分野別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場動向

  • イントロダクション
  • 市場促進因子
  • 市場阻害因子
  • 機会
  • ポーターズファイブフォース分析
  • 市場の魅力度分析

第4章 競合環境

  • 企業市場シェア分析
  • 戦略的発展
  • 価格動向分析

第5章 治療タイプ別

  • 概要
  • モノクローナル抗体
  • 免疫チェックポイント阻害剤
  • 免疫系変調因子
  • 癌ワクチン
  • その他

第6章 治療分野別

  • 概要
  • 肺癌
  • 大腸癌
  • 乳癌
  • 前立腺癌
  • メラノーマ
  • 血液癌
  • その他

第7章 エンドユーザー別

  • 概要
  • 病院
  • クリニック
  • 外来外科センター
  • 癌研究機関

第8章 地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 企業プロファイル

  • Amgen, Inc
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Janssen Biotech
  • Merck and Co
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • Spectrum Pharmaceuticals, Inc.
  • 武田薬品工業株式会社
目次

The report covers forecast and analysis for the immuno-oncology therapy market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based revenue (USD Billion). The study includes drivers and restraints for the immuno-oncology therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the immuno-oncology therapy market on a global level.

In order to give the users of this report a comprehensive view of the immuno-oncology therapy market, we have included competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein therapy type segment, therapeutic area segment, and end-user segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new technology launch, agreements, partnerships, collaborations joint ventures, research development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.

The study provides a decisive view on the immuno-oncology therapy market by segmenting the market based on therapy type, therapeutic area, end-user, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2016 to 2022. Based on therapy type the market is segmented into monoclonal antibodies, immune checkpoint inhibitors (PD1/ PDL1 and CTLA-4), immune system modulators, cancer vaccines and others. Based on the therapeutic area the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, blood cancer and other cancers. Key end-users covered under this study include hospitals, clinics, ASCs and cancer research institutes. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East Africa with its further bifurcation into major countries including the U.S., Canada, Rest of North America, U.K., Germany, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, Australia, Rest of Asia Pacific, Brazil, Mexico, Argentina, Rest of Latin America, Saudi Arabia, UAE, Qatar, South Africa and Rest of Middle East and Africa. This segmentation includes demand for immuno-oncology therapy market based on individual therapy type, therapeutic area and end-users in all the regions and countries.

The report also includes detailed profiles of end players such as Amgen, Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Merck and Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals, Inc. and Takeda Pharmaceuticals.

This report segments the global immuno-oncology therapy market as follows:

Global Immuno-oncology Therapy Market: Therapy Type Segment Analysis

  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • PD-1/ PD-L1
  • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Others

Global Immuno-oncology Therapy Market: Therapeutic Area Segment Analysis

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Melanoma
  • Blood Cancer
  • Others Cancers

Global Immuno-oncology Therapy Market: End-user Segment Analysis

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Cancer Research Institutes

Global Immuno-oncology Therapy Market: Regional Segment Analysis

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa

Table of Contents

Chapter 1. Introduction

  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology

Chapter 2. Executive Summary

  • 2.1. Global Immuno-oncology Therapy Market, 2016 2022 (USD Billion)
  • 2.2. Global Immuno-oncology Therapy Market: Snapshot

Chapter 3. Immuno-oncology Therapy Market Market Dynamics

  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Global immuno-oncology therapy market drivers: Impact analysis
    • 3.2.2. Highly Promising Treatment Pipeline
    • 3.2.3. Increase in Number of Patients Suffering from Various Cancers
    • 3.2.4. Greater Efficiency Over Conventional Treatment Methods
  • 3.3. Market Restraints
    • 3.3.1. Global immuno-oncology therapy market restraints: Impact analysis
    • 3.3.2. High Level of Attrition within the Development Cycles
    • 3.3.3. Stringent Regulatory Framework
    • 3.3.4. Lack of Awareness of Immunotherapy
  • 3.4. Opportunities
    • 3.4.1. Developed Economies Showing Higher Development Rates
  • 3.5. Porters five forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. Threat from new entrants
    • 3.5.4. Threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by therapy type segment
    • 3.6.2. Market attractiveness analysis, by end-user segment
    • 3.6.3. Market attractiveness analysis, by regional segment

Chapter 4. Global Immuno-oncology Therapy Market Competitive Landscape

  • 4.1. Company Market Share Analysis
    • 4.1.1. Global immuno-oncology therapy market: company market share, 2016
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions Mergers
    • 4.2.2. New Therapy Launch
    • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
    • 4.2.4. Research and Development and Regional Expansion
  • 4.3. Price Trend Analysis

Chapter 5. Global Immuno-oncology Therapy Market Therapy Type Segment Analysis

  • 5.1. Global immuno-oncology therapy market: therapy type overview
    • 5.1.1. Global immuno-oncology therapy market revenue share, by therapy type, 2016 and 2022
  • 5.2. Monoclonal Antibodies
    • 5.2.1. Global immuno-oncology therapy market for monoclonal antibodies market, 2016 2022 (USD Billion)
  • 5.3. Immune Checkpoint Inhibitors
    • 5.3.1. Global immuno-oncology therapy market for immune checkpoint inhibitors market, 2016 2022 (USD Billion)
      • 5.3.1.1. Global immuno-oncology therapy market for PD1/ PDL1 market, 2016 2022 (USD Billion)
      • 5.3.1.2. Global immuno-oncology therapy market for CTLA-4 market, 2016 2022 (USD Billion)
  • 5.4. Immune System Modulators
    • 5.4.1. Global immuno-oncology therapy market for immune system modulators market, 2016 2022 (USD Billion)
  • 5.5. Cancer Vaccines
    • 5.5.1. Global immuno-oncology therapy market for cancer vaccines market, 2016 2022 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global immuno-oncology therapy market for others market, 2016 2022 (USD Billion)

Chapter 6. Global Immuno-oncology Therapy Market Therapeutic Area Segment Analysis

  • 6.1. Global immuno-oncology therapy market: therapeutic area overview
    • 6.1.1. Global immuno-oncology therapy market revenue share, by therapeutic area, 2016 and 2022
  • 6.2. Lung Cancer
    • 6.2.1. Global immuno-oncology therapy market for lung cancer market, 2016 2022 (USD Billion)
  • 6.3. Colorectal Cancer
    • 6.3.1. Global immuno-oncology therapy market for colorectal cancer market, 2016 2022 (USD Billion)
  • 6.4. Breast Cancer
    • 6.4.1. Global immuno-oncology therapy market for breast cancer market, 2016 2022 (USD Billion)
  • 6.5. Prostate Cancer
    • 6.5.1. Global immuno-oncology therapy market for prostate cancer market, 2016 2022 (USD Billion)
  • 6.6. Melanoma
    • 6.6.1. Global immuno-oncology therapy market for melanoma market, 2016 2022 (USD Billion)
  • 6.7. Blood Cancer
    • 6.7.1. Global immuno-oncology therapy market for blood cancer market, 2016 2022 (USD Billion)
  • 6.8. Other Cancers
    • 6.8.1. Global immuno-oncology therapy market for other cancers market, 2016 2022 (USD Billion)

Chapter 7. Global Immuno-oncology Therapy Market End-User Segment Analysis

  • 7.1. Global immuno-oncology therapy market: end-user overview
    • 7.1.1. Global immuno-oncology therapy market revenue share, by end-user, 2016 and 2022
  • 7.2. Hospitals
    • 7.2.1. Global immuno-oncology therapy market for hospitals 2016 2022 (USD Billion)
  • 7.3. Clinics
    • 7.3.1. Global immuno-oncology therapy market for clinics, 2016 2022 (USD Billion)
  • 7.4. Ambulatory Surgical Centers (ASCs)
    • 7.4.1. Global immuno-oncology therapy market for ambulatory surgical centers, 2016 2022 (USD Billion)
  • 7.5. Cancer Research Institutes
    • 7.5.1. Global immuno-oncology therapy market for cancer research institutes end-users, 2016 2022 (USD Billion)

Chapter 8. Global Immuno-oncology Therapy Market Regional Segment Analysis

  • 8.1. Global immuno-oncology therapy market: regional overview
    • 8.1.1. Global immuno-oncology therapy market revenue share, by region, 2016 and 2022
  • 8.2. North America
    • 8.2.1. North America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
    • 8.2.2. North America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
    • 8.2.3. North America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.2.4. U.S.
      • 8.2.4.1. U.S. Immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.2.4.2. U.S. Immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.2.4.3. U.S. Immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.2.5. Canada
      • 8.2.5.1. Canada immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.2.5.2. Canada immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.2.5.3. Canada immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.2.6. Rest of North America
      • 8.2.6.1. Rest of North America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.2.6.2. Rest of North America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.2.6.3. Rest of North America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
    • 8.3.2. Europe immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
    • 8.3.3. Europe immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.3.4. U.K.
      • 8.3.4.1. U.K. Immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.3.4.2. U.K. Immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.3.4.3. U.K. Immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.3.5. Germany
      • 8.3.5.1. Germany immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.3.5.2. Germany immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.3.5.3. Germany immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.3.6. France
      • 8.3.6.1. France immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.3.6.2. France immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.3.6.3. France immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.3.7. Italy
      • 8.3.7.1. Italy immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.3.7.2. Italy immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.3.7.3. Italy immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.3.8. Spain
      • 8.3.8.1. Spain immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.3.8.2. Spain immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.3.8.3. Spain immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.3.9. Russia
      • 8.3.9.1. Russia immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.3.9.2. Russia immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.3.9.3. Russia immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.3.10. Rest of Europe
      • 8.3.10.1. Rest of Europe immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.3.10.2. Rest of Europe immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.3.10.3. Rest of Europe immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
    • 8.4.2. Asia Pacific immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
    • 8.4.3. Asia Pacific immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.4.4. China
      • 8.4.4.1. China immuno-oncology therapy market revenue, by therapy type, 2016 2022(USD Billion)
      • 8.4.4.2. China immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.4.4.3. China immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.4.5. Japan
      • 8.4.5.1. Japan immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.4.5.2. Japan immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.4.5.3. Japan immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.4.6. India
      • 8.4.6.1. India immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.4.6.2. India immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.4.6.3. India immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.4.7. Australia
      • 8.4.7.1. Australia immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.4.7.2. Australia immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.4.7.3. Australia immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.4.8. Rest of Asia Pacific
      • 8.4.8.1. Rest of Asia Pacific immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.4.8.2. Rest of Asia Pacific immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.4.8.3. Rest of Asia Pacific immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
    • 8.5.2. Latin America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
    • 8.5.3. Latin America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.5.4. Brazil
      • 8.5.4.1. Brazil immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.5.4.2. Brazil immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.5.4.3. Brazil immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.5.5. Mexico
      • 8.5.5.1. Mexico immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.5.5.2. Mexico immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.5.5.3. Mexico immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.5.6. Argentina
      • 8.5.6.1. Argentina immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.5.6.2. Argentina immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.5.6.3. Argentina immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.5.7. Rest of Latin America
      • 8.5.7.1. Rest of Latin America immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.5.7.2. Rest of Latin America immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.5.7.3. Rest of Latin America immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
    • 8.6.2. Middle East and Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
    • 8.6.3. Middle East and Africa immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Saudi Arabia immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.6.4.2. Saudi Arabia immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.6.4.3. Saudi Arabia immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.6.5. UAE
      • 8.6.5.1. UAE immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.6.5.2. UAE immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.6.5.3. UAE immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.6.6. Qatar
      • 8.6.6.1. Qatar immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.6.6.2. Qatar immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.6.6.3. Qatar immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.6.7. South Africa
      • 8.6.7.1. South Africa immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.6.7.2. South Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.6.7.3. South Africa immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)
    • 8.6.8. Rest of Middle East and Africa
      • 8.6.8.1. Rest of Middle East and Africa immuno-oncology therapy market revenue, by therapy type, 2016 2022 (USD Billion)
      • 8.6.8.2. Rest of Middle East and Africa immuno-oncology therapy market revenue, by therapeutic area, 2016 2022 (USD Billion)
      • 8.6.8.3. Rest of Middle East and Africa immuno-oncology therapy market revenue, by end-user, 2016 2022 (USD Billion)

Chapter 9. Company Profile

  • 9.1. Amgen, Inc.
    • 9.1.1. Overview
    • 9.1.2. Financials
    • 9.1.3. Therapy portfolio
    • 9.1.4. Business strategy
    • 9.1.5. Recent developments
  • 9.2. AstraZeneca Plc.
    • 9.2.1. Overview
    • 9.2.2. Financials
    • 9.2.3. Therapy portfolio
    • 9.2.4. Business strategy
    • 9.2.5. Recent developments
  • 9.3. Bristol-Myers Squibb Company
    • 9.3.1. Overview
    • 9.3.2. Financials
    • 9.3.3. Therapy portfolio
    • 9.3.4. Business strategy
    • 9.3.5. Recent developments
  • 9.4. Eli Lilly and Company
    • 9.4.1. Overview
    • 9.4.2. Financials
    • 9.4.3. Therapy portfolio
    • 9.4.4. Business strategy
    • 9.4.5. Recent developments
  • 9.5. F.Hoffmann-La Roche Ltd.
    • 9.5.1. Overview
    • 9.5.2. Financials
    • 9.5.3. Therapy portfolio
    • 9.5.4. Business strategy
    • 9.5.5. Recent developments
  • 9.6. GlaxoSmithKline Plc.
    • 9.6.1. Overview
    • 9.6.2. Financials
    • 9.6.3. Therapy portfolio
    • 9.6.4. Business strategy
    • 9.6.5. Recent developments
  • 9.7. Janssen Biotech
    • 9.7.1. Overview
    • 9.7.2. Financials
    • 9.7.3. Therapy portfolio
    • 9.7.4. Business strategy
    • 9.7.5. Recent developments
  • 9.8. Merck and Co.
    • 9.8.1. Overview
    • 9.8.2. Financials
    • 9.8.3. Therapy portfolio
    • 9.8.4. Business strategy
    • 9.8.5. Recent developments
  • 9.9. Novartis AG
    • 9.9.1. Overview
    • 9.9.2. Financials
    • 9.9.3. Therapy portfolio
    • 9.9.4. Business strategy
    • 9.9.5. Recent developments
  • 9.10. Pfizer, Inc.
    • 9.10.1. Overview
    • 9.10.2. Financials
    • 9.10.3. Therapy portfolio
    • 9.10.4. Business strategy
    • 9.10.5. Recent developments
  • 9.11. Sanofi
    • 9.11.1. Overview
    • 9.11.2. Financials
    • 9.11.3. Therapy portfolio
    • 9.11.4. Business strategy
    • 9.11.5. Recent developments
  • 9.12. Spectrum Pharmaceuticals, Inc.
    • 9.12.1. Overview
    • 9.12.2. Financials
    • 9.12.3. Therapy portfolio
    • 9.12.4. Business strategy
    • 9.12.5. Recent developments
  • 9.13. Takeda Pharmaceuticals
    • 9.13.1. Overview
    • 9.13.2. Financials
    • 9.13.3. Therapy portfolio
    • 9.13.4. Business strategy
    • 9.13.5. Recent developments
Back to Top